MARKET

CANF

CANF

CAN FITE BIOPHAR
AMEX

Real-time Quotes | Nasdaq Last Sale

1.500
0.000
0.00%
After Hours: 1.510 +0.01 +0.67% 18:16 02/21 EST
OPEN
1.550
PREV CLOSE
1.500
HIGH
1.680
LOW
1.480
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
24.30
52 WEEK LOW
1.080
MARKET CAP
4.99M
P/E (TTM)
-0.2230
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CANF and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CANF stock price target is 7.00 with a high estimate of 9.00 and a low estimate of 5.00.

EPS

CANF News

More
  • Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
  • Business Wire · 4d ago
  • Can-Fite up 4% premarket on advancement of Namodenoson study in liver cancer
  • Seeking Alpha - Article · 02/13 14:26
  • Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson
  • Business Wire · 02/13 12:00
  • Can-Fite BioPharma Prices ~3.33M Unit Offering At $1.50/Unit
  • Benzinga · 02/10 19:50

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CANF

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
More

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.